A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Adigweme I, Yisa M, Ooko M, Akpalu E, Bruce A, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, Segonds-Pichon A, Njie A, Crooke S, El-Badry E, Johnstone H, Royals M, Goodson JL, Prausnitz MR, McAllister DV, Rota PA, Henry S, Clarke E.
Adigweme I, et al.
Lancet. 2024 May 11;403(10439):1879-1892. doi: 10.1016/S0140-6736(24)00532-4. Epub 2024 Apr 29.
Lancet. 2024.
PMID: 38697170
Free PMC article.
Clinical Trial.
In infants, 93% (52/56; 95% CI 83.0-97.2) seroconverted to measles and 100% (58/58; 93.8-100) seroconverted to rubella following MRV-MNP administration, while 90% (52/58; 79.2-95.2) and 100% (59/59; 93.9-100) seroconverted to measles and rubella respectively, following MRV-SC. …
In infants, 93% (52/56; 95% CI 83.0-97.2) seroconverted to measles and 100% (58/58; 93.8-100) seroconverted to rubella following MRV-MNP adm …